La FDA ha aprobado Daraxonrasib (Rasonque) un inhibidor de la familia RAS para tratar el cáncer de páncreas metastásico.

FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma?utm_medium=email&_hsenc=p2ANqtz---Kk3eS_XnTzNNMp3RCJzglcAh5LgTeKVaIBFxcnChEclFsqGwzwBBzHt_5m_4hqzIAwwGNhYTdqqYoz4S4qCZJWWmPQ&_hsmi=144840094&utm_content=144848639&utm_source=hs_email